161 related articles for article (PubMed ID: 38333526)
1. Exploratory clinical subgroup clustering in systemic sclerosis: Results from the Indian Progressive Systemic Sclerosis Registry.
Philip SS; Janardana R; Shenoy P; Kavadichanda C; Bairwa D; Sircar G; Ghosh P; Wakhlu A; Selvam S; Khanna D; Shobha V
J Scleroderma Relat Disord; 2024 Feb; 9(1):29-37. PubMed ID: 38333526
[TBL] [Abstract][Full Text] [Related]
2. Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohorts.
Liem SIE; Boonstra M; le Cessie S; Riccardi A; Airo P; Distler O; Matucci-Cerinic M; Caimmi C; Siegert E; Allanore Y; Huizinga TWJ; Toes REM; Scherer HU; de Vries-Bouwstra JK;
Lancet Rheumatol; 2022 Oct; 4(10):e699-e709. PubMed ID: 38265968
[TBL] [Abstract][Full Text] [Related]
3. Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry.
Tolosa-Vilella C; Morera-Morales ML; Simeón-Aznar CP; Marí-Alfonso B; Colunga-Arguelles D; Callejas Rubio JL; Rubio-Rivas M; Freire-Dapena M; Guillén-Del Castillo A; Iniesta-Arandia N; Castillo-Palma MJ; Egurbide-Arberas M; Trapiellla-Martínez L; Vargas-Hitos JA; Todolí-Parra JA; Rodriguez-Carballeira M; Marin-Ballvé A; Pla-Salas X; Rios-Blanco JJ; Fonollosa-Pla V;
Semin Arthritis Rheum; 2016 Oct; 46(2):200-208. PubMed ID: 27312381
[TBL] [Abstract][Full Text] [Related]
4. Clinical and autoantibody profiles of systemic sclerosis patients: A cross-sectional study from North India.
Ghosh S; Tanna D; Telang K; Dhuria S; Gupta R
Indian J Dermatol Venereol Leprol; 2023 Jul; ():1-7. PubMed ID: 37436007
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of patients with systemic sclerosis living in Qatar.
Alam F; Abdulaziz HM; Ul Haq I; Mahdy SM; Mohammed Siam AR; Chandra P; Al Emadi S
Qatar Med J; 2019; 2019(3):16. PubMed ID: 31903322
[No Abstract] [Full Text] [Related]
6. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
[TBL] [Abstract][Full Text] [Related]
7. Systemic Sclerosis and Pulmonary Disease.
Ngo K
Adv Exp Med Biol; 2021; 1303():173-182. PubMed ID: 33788193
[TBL] [Abstract][Full Text] [Related]
8. Unique clinical and autoantibody profile of a large Asian Indian cohort of scleroderma-do South Asians have a more aggressive disease?
Janardana R; Nair AM; Surin AK; Prakash JAJ; Gowri M; Danda D
Clin Rheumatol; 2019 Nov; 38(11):3179-3187. PubMed ID: 31309339
[TBL] [Abstract][Full Text] [Related]
9. [Autoantibodies in systemic sclerosis and their clinical correlation in patients from a Midwestern region of Brazil].
Coelho Horimoto AM; da Costa IP
Rev Bras Reumatol; 2015; 55(3):229-39. PubMed ID: 25559063
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous Features, Autoantibody Profile, and Nailfold Capillaroscopy of Systemic Sclerosis: A Study of 60 Cases.
Dave J; Mahajan S; Khadilkar P; Pradhan V
J Assoc Physicians India; 2022 Nov; 70(11):11-12. PubMed ID: 37355940
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation, prognosis and pathogenesis.
Grassegger A; Pohla-Gubo G; Frauscher M; Hintner H
Wien Med Wochenschr; 2008; 158(1-2):19-28. PubMed ID: 18286246
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive description of the prevalence, serological and clinical characteristics, and visceral involvement of systemic sclerosis (scleroderma) in a large cohort from the United Arab Emirates Systemic Sclerosis Registry.
Namas R; Elarabi M; Khan S; Mubashir A; Memisoglu E; El-Kaissi M; Joshi A; Chapman J; Jassim I; Khogali H; Hassan N; Sabbour H; Saleh K; Alnaqbi KA; Zayat AS; Diab S; Awir Z; Abu Taha N; Ginawi A; Al Ansari A; Rifaai H; Alrawi Z; Al Dhaheri A; Ibrahim G; Abogamal A; Al Shehhi W; Teir J; Khan T; Musgrave M; Hameed B; Khan B; Mosallam N; Hussien N; Hussein I; Abdulelhamid A; Ali A; Hannawi S; Al Izzi M; Badsha H; Al Saleh J
J Scleroderma Relat Disord; 2023 Jun; 8(2):137-150. PubMed ID: 37287950
[TBL] [Abstract][Full Text] [Related]
13. [Clinical features of systemic sclerosis and association with antitopoisomerase-1 antibody and centromere pattern of antinuclear antibody].
Bertazzi GR; de Toledo RA; de Godoy MF; Geraldino GC; Polizelli DV; Fernandes GC; Pedroso CL; dos Santos FG; de Assis TM
Acta Reumatol Port; 2012; 37(1):9-17. PubMed ID: 22781510
[TBL] [Abstract][Full Text] [Related]
14. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.
Sánchez-Cano D; Ortego-Centeno N; Callejas JL; Fonollosa Plá V; Ríos-Fernández R; Tolosa-Vilella C; Espinosa-Garriga G; Colunga-Argüelles D; Egurbide-Arberas MV; Rubio-Rivas M; Freire M; Ríos-Blanco JJ; Trapiella-Martínez L; Rodríguez-Carballeira M; Marín-Ballvé A; Pla-Salas X; Simeón-Aznar CP
Rheumatol Int; 2018 Mar; 38(3):363-374. PubMed ID: 29322341
[TBL] [Abstract][Full Text] [Related]
15. Anti-RNA polymerase III antibodies in patients with suspected and definite systemic sclerosis: Why and how to screen.
Lazzaroni MG; Airò P
J Scleroderma Relat Disord; 2018 Oct; 3(3):214-220. PubMed ID: 35382018
[TBL] [Abstract][Full Text] [Related]
16. Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry 'SPRING' of the Italian Society for Rheumatology.
De Angelis R; Ferri C; Giuggioli D; Bajocchi G; Dagna L; Bellando-Randone S; Zanframundo G; Foti R; Cacciapaglia F; Cuomo G; Ariani A; Rosato E; Lepri G; Girelli F; Riccieri V; Zanatta E; Bosello SL; Cavazzana I; Ingegnoli F; De Santis M; Murdaca G; Abignano G; Romeo N; Della Rossa A; Caminiti M; Iuliano AM; Ciano G; Beretta L; Bagnato G; Lubrano E; De Andres I; Giollo A; Saracco M; Agnes C; Cipolletta E; Lumetti F; Spinella A; Magnani L; Campochiaro C; De Luca G; Codullo V; Visalli E; Di Vico C; Gigante A; Pellagrino G; Pigatto E; Lazzaroni MG; Franceschini F; Generali E; Mennillo G; Barsotti S; Mariano GP; Furini F; Vultaggio L; Parisi S; Peroni CL; Rozza D; Zanetti A; Carrara G; Landolfi G; Scirè CA; Bianchi G; Fusaro E; Sebastiani GD; Govoni M; D'Angelo S; Cozzi F; Guiducci S; Doria A; Salvarani C; Iannone F; Matucci-Cerinic M;
RMD Open; 2023 Mar; 9(1):. PubMed ID: 36868782
[TBL] [Abstract][Full Text] [Related]
17. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.
Srivastava N; Hudson M; Tatibouet S; Wang M; Baron M; Fritzler MJ;
Semin Arthritis Rheum; 2015 Oct; 45(2):184-9. PubMed ID: 25959492
[TBL] [Abstract][Full Text] [Related]
18. [Assessment of serum IgG activity correlation against cyclic citrullinated peptide antibodies, topoisomerase I and centromere proteins in Mexican patients with progressive systemic sclerosis].
Rocha-Muñoz AD; González-López L; Peguero-Gómez R; Aguilar-Chávez EA; Villa-Manzano AI; Corona-Sánchez E; Galván-Méndez S; Presiado-Sánchez C; Vázquez-Jiménez JC; Riebeling C; Salazar-Páramo M; Gámez-Nava JI; Nava A
Rev Alerg Mex; 2009; 56(4):103-7. PubMed ID: 19768971
[TBL] [Abstract][Full Text] [Related]
19. Case of diffuse cutaneous systemic sclerosis with anti-Ku and anti-centromere antibodies.
Ohashi S; Ueda-Hayakawa I; Isei T; Okamoto H
J Dermatol; 2013 Jul; 40(7):558-61. PubMed ID: 23663134
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the clinical phenotype of systemic sclerosis patients in Iran and France in two university centers.
Allanore Y; Gharibdoost F; Jamshidi AR; Javinani A; Avouac J; Rastkar E; Hooshmandi S; Kavosi H
J Scleroderma Relat Disord; 2019 Jun; 4(2):149-159. PubMed ID: 35382390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
